Telehealth has emerged as a critical tool in managing heart failure (HF), offering significant benefits in improving patient care, optimizing resources, and enhancing outcomes. The article reviews the potential of telehealth technologies, including telemedicine, wearable devices, and remote invasive hemodynamic monitoring, in addressing HF. Telemedicine enables remote patient monitoring, facilitating timely interventions and reducing hospitalizations. Wearable technology, such as smartwatches and sensor patches, allows continuous monitoring of vital signs, aiding in early detection of HF exacerbations. Cardiac implantable electronic devices (CIEDs) provide valuable diagnostic information, including thoracic impedance, which can predict fluid congestion and mortality risk. Remote invasive hemodynamic monitoring, such as the CardioMEMS system, offers real-time data on pulmonary pressures, improving management of advanced HF. Telehealth also plays a crucial role in post-transplant care and LVAD management, ensuring continuous monitoring and timely interventions. Artificial intelligence (AI) is increasingly integrated into telemedicine, enhancing diagnostic accuracy and enabling proactive management of HF. Despite these advancements, challenges remain, including ensuring equitable access and addressing technological barriers. The cost-effectiveness of telehealth interventions in HF is promising, with studies indicating potential cost savings through reduced hospitalizations. Overall, telehealth represents a transformative approach in HF management, offering a pathway to more personalized, efficient, and effective care.Telehealth has emerged as a critical tool in managing heart failure (HF), offering significant benefits in improving patient care, optimizing resources, and enhancing outcomes. The article reviews the potential of telehealth technologies, including telemedicine, wearable devices, and remote invasive hemodynamic monitoring, in addressing HF. Telemedicine enables remote patient monitoring, facilitating timely interventions and reducing hospitalizations. Wearable technology, such as smartwatches and sensor patches, allows continuous monitoring of vital signs, aiding in early detection of HF exacerbations. Cardiac implantable electronic devices (CIEDs) provide valuable diagnostic information, including thoracic impedance, which can predict fluid congestion and mortality risk. Remote invasive hemodynamic monitoring, such as the CardioMEMS system, offers real-time data on pulmonary pressures, improving management of advanced HF. Telehealth also plays a crucial role in post-transplant care and LVAD management, ensuring continuous monitoring and timely interventions. Artificial intelligence (AI) is increasingly integrated into telemedicine, enhancing diagnostic accuracy and enabling proactive management of HF. Despite these advancements, challenges remain, including ensuring equitable access and addressing technological barriers. The cost-effectiveness of telehealth interventions in HF is promising, with studies indicating potential cost savings through reduced hospitalizations. Overall, telehealth represents a transformative approach in HF management, offering a pathway to more personalized, efficient, and effective care.